Proshares UltraShort Nasdaq Biotech

Peraso

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

Decent

Edesa Biotech

Cre8 Enterprise - CL

AN2 Therapeutics

Day One Biopharmaceuticals

Epsium Enterprise

Silynxcom

Aptera Motors - B

IBBQ

SBIO

ARKG

LABU

Nuvau Minerals Raises $21.4 Million in Final Tranche of Brokered Financing

Tip Ranks

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Nuvau Minerals Raises $21.4 Million in Final Tranche of Brokered Financing

588250

588130

March 5 (Reuters) -* COGNITO THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $105 MILLION SERIES C FINANCING TO ADVANCE SPECTRIS™ IN ALZHEIMER’S DISEASE Source text: Further company coverage: [ ]

Reuters

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing To Advance Spectris™ In Alzheimer’S Disease

Cytophage Technologies Ltd. has formed a special committee of independent directors to evaluate strategic alternatives, including unsolicited financing proposals. The committee will oversee a competitive process for interested parties to conduct due diligence and potentially reach a financing agreement. Options may include a merger, sale, or other business combinations. The Board has not set a timetable for this process and will not provide updates unless necessary. Cytophage focuses on bacteriophage research to combat antibiotic resistance in animal health and food security.

The newswire.ca

Cytophage Announces Formation of Special Committee of Independent Directors to Evaluate Strategic Alternatives

Halia Therapeutics, a clinical-stage biopharmaceutical company, announced its presentation at the BIO Investment & Growth Summit on March 2, 2026. CEO David Bearss will discuss the company's strategy, platform, and clinical programs. Halia focuses on developing first-in-class inflammasome inhibitors to address inflammation-driven diseases by targeting NEK7, a key regulator of inflammasome activation.

prnewswire

VG Health

Health Care Select Sector SPDR

iShares US Pharma

08:35 ETHalia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

SMIN

NFTY

Cipla enters JV with Kemwell Biopharma for biologic products

marketscreener

ISHRS MSCI India S-Cap

First Trust India Nifty 50 Equal Weight

Nippon Life Insurance Co.

ISHRS MSCI India

Xtrackers Nifty 500 India ETF

Cipla enters JV with Kemwell Biopharma for biologic products

Aspen Pharmacare plans to register its unbranded version of Ozempic in Canada by the second or third quarter of 2023. CEO Stephen Saad indicated that feedback from regulators suggests a potential registration between May and September. This move aims to establish Aspen as a leading provider of generic competition for Ozempic following the expiration of Novo Nordisk's patent on semaglutide in January.

Guotai CSI Bio-medicine ETF

Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter

On March 4, 2026, ProMIS Neurosciences director Eugene Williams purchased 4,000 shares, valued at $92,420, indicating confidence in the company's future. However, TipRanks' AI Analyst rates PMN as Neutral due to weak financials, including no revenue and significant losses. While technicals are strong, the company faces risks from potential dilution and reliance on external funding. ProMIS has seen a 260.70% year-to-date price increase, with a current market cap of $52.95M.

ProMIS Neurosciences

Top ProMIS Neurosciences Insider Quietly Makes a Bold New Bet

Psyence Biomedical Ltd. (Nasdaq: PBM) disclosed today that they have exported a fully GMP-compliant psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. This move signifies the company's commitment to advancing nature-derived psilocybin and ibogaine therapies for unaddressed mental health concerns. The product was manufactured at Psyence Labs Ltd. (“PsyLabs”) GMP-controlled production facility, emphasizing their dedication to pharmaceutical-grade psychedelic development.

Unusual Whales

Psyence BioMed exports GMP-manufactured psilocybin to Australia for Phase IIb trial. Product includes 1mg & 5mg capsules.

516500

159849

Veeva Systems (NYSE:VEEV) reported Q4 revenue of $836M, exceeding estimates, and provided FY27 guidance above expectations. The stock surged 11.3% in pre-market trading. Analysts adjusted their price targets post-earnings, with Piper Sandler lowering it from $355 to $285 and Needham from $355 to $270, while maintaining their ratings. The company’s Q4 earnings per share were $2.06, beating the consensus of $1.93, and it expects Q1 revenue between $855M and $858M, above analyst forecasts.

benzinga_article

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

These Analysts Cut Their Forecasts On Veeva Systems Following Q4 Results

A weak U.S. jobs report revealed a surprising loss of 28,000 jobs in the health care sector, raising concerns about the stability of health care ETFs like the Health Care Select Sector SPDR ETF (XLV). Traditionally viewed as a safe investment, the sector's decline may signal broader implications for the market, especially as health care is a significant component of major index ETFs. Despite the recent downturn, the sector has shown resilience, with XLV returning 11% over the past six months. Investors are advised to monitor these developments closely.

SPDR S&P Health

iShares Global Healthcare

SPDR S&P Health Equip

iShares US Medical Devices

Jobs Report Just Dented Most Bulletproof Sector ETF In The Market

159898

159883

C8 Health launched a new AI platform on March 3, 2026, in New York, aimed at improving perioperative glucose-testing compliance by nearly 10%. The platform, presented at the Society for Perioperative Assessment and Quality Improvement (SPAQI), provides evidence-based guidelines for clinical teams to enhance healthcare quality. Data from an ongoing observational study indicates significant improvements in patient outcomes, supporting SPAQI's mission to advance perioperative care.

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Hwabao WP CSI Medical Service ETF

ChinaAMC CSI All Share Health Care Devices ETF

C8 Health AI platform boosts perioperative glucose-testing compliance by nearly 10% - presented at SPAQI.

March 5 (Reuters) - Arvana Inc (AVNI.PK) :* ARVANA INC: FILES PROSPECTUS RELATED TO RESALE FROM TIME TO TIME OF UP TO 15 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER- SEC FILING Source text: [] Further company coverage: (AVNI.PK)

Arvana Inc Files Prospectus Related To Resale From Time To Time Of Up To 15 Million Shares Of Common Stock By Selling Stockholder- SEC Filing

Robbins LLP has announced a class action lawsuit on behalf of investors who acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive misled investors regarding the approval status of its drug Anaphylm, leading to a significant stock price drop of over 37% following the revelation of FDA deficiencies. Shareholders interested in participating in the class action can contact Robbins LLP for more information.

15:56 ETAQST Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aquestive Therapeutics, Inc.

Gallant, an animal health biotechnology company, has announced a partnership with MWI Animal Health to establish the first ultra-low temperature cold chain in veterinary medicine. This initiative aims to deliver the anticipated first FDA-approved off-the-shelf stem cell therapy for pets, specifically targeting conditions like refractory feline chronic gingivostomatitis. The partnership will ensure reliable distribution and access to these therapies across the U.S., addressing the growing demand for regenerative veterinary treatments.

VanEck Pharmaceutical ETF

SPDR Pharmac

Invesco Pharmaceuticals ETF

10:38 ETGallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics

VentriPoint Diagnostics Ltd. announced that the integration of AI in the medical field is rapidly increasing. According to a recent report by USANewsGroup.com, the AI medical imaging market is experiencing significant growth. In particular, the adoption of AI technology in medical systems is progressing swiftly, with the integration hastening.

Ping An CSI Medicine and Medical Device Innovation ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

Hospital networks are increasingly embracing AI-enhanced cardiac imaging to save costs and enhance outcomes. AI implementation in medical imaging is rapidly growing.

Proshares UltraShort Nasdaq Biotech(BIS.US)

Nuvau Minerals Raises $21.4 Million in Final Tranche of Brokered Financing

Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing To Advance Spectris™ In Alzheimer’S Disease

Cytophage Announces Formation of Special Committee of Independent Directors to Evaluate Strategic Alternatives

08:35 ETHalia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

Cipla enters JV with Kemwell Biopharma for biologic products